Who is eligible?
Eligible participants for these studies must:
- Be male or female, 12 years of age or older
- Have chronic atopic dermatitis for at least one year
- Have a history of inadequate response to topical treatments for atopic dermatitis
Additional eligibility criteria will be assessed by the study doctor or staff during the screening process prior to being enrolled in one of these studies and receiving any investigational medication. Not all individuals will qualify to participate.
What to expect.
Participation in one of the ADvocate Studies lasts approximately 56 weeks and consists of three parts:
- During a screening period of up to 30 days, the study doctor will perform tests and procedures to determine if you or your child is eligible to participate.
- If eligible, you or your child will enter the 52-week treatment period and begin receiving the investigational medication or a placebo (which contains no active medication), both of which are delivered as an injection.
- If eligible, you or your child may continue receiving the investigational medication in a separate long-term extension study. Or you or your child may stop participating by receiving a safety follow-up phone call 12 weeks after the last dose of investigational medication
Those who qualify will receive either the investigational medication or a placebo, as well as study-related medical exams and laboratory tests, all at no cost. Compensation for travel may also be available.
In both studies, participants will be randomly assigned to a study group. You or your child will receive either the investigational medication or a placebo, depending on the assigned study group. Neither you nor the study team will know which study group you or your child is in, but in the case of an emergency, the study doctor can quickly find out.